• Home
  • Study Details


The purpose of this study is to find out if a medicine called finerenone in combination with a medicine called empagliflozin is a safe and effective treatment for people that chronic kidney disease and type 2 diabetes.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Visit Availability

  • Standard business hours (M-F, 8-5)
  • Visits can be combined with regular clinical appointments


North Carolina (Statewide)

What will be asked of you

Study visits will be like regular doctor appointments. At these visits, we will measure your vital signs (blood pressure, weight, height), conduct an ECG (test to measure heart function), the study doctor will complete a brief physical exam, and we will collect blood and urine samples.



In-person visits:
Total length of participation:
8 months

Looking for Specific Volunteers

Able to participate:

  • Chronic Kidney Disease
  • Type 2 Diabetes

Not eligible if:

  • Type 1 Diabetes

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Visit Study Website

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Secondary Visit Location

UNC Eastowne Medical Office Building
100 Eastowne Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Amy Mottl

Study Type

Clinical or Medical

Study Topics

Kidneys and Liver
Rare Diseases

IRB Number




Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research